Adenosine Deaminase (ADA)(Pericardial Fluid)

Blood

Report in 24Hrs

At Home

No Fasting Required

Details

ADA enzyme activity in pericardial fluid.

₹222₹317

30% OFF

Adenosine Deaminase (ADA) - Pericardial Fluid

Why is it done?
- Test Purpose: Measures adenosine deaminase enzyme levels in pericardial fluid to aid in differential diagnosis of pericardial effusion and pericarditis
- Primary Indications: Diagnosis of tuberculous pericarditis when pericardial fluid is present; differentiation between tuberculous and non-tuberculous causes of pericardial effusion; assessment of pericardial inflammation in patients with clinical suspicion of tuberculosis
- Typical Clinical Scenarios: Unexplained pericardial effusion; recurrent pericarditis; suspected tuberculosis with pericardial involvement; immunocompromised patients with pericardial disease; confirmation of tuberculous etiology when other tests are inconclusive
- Clinical Context: Performed during diagnostic pericardiocentesis when pericardial fluid analysis is being conducted for diagnostic purposes
Normal Range
- Reference Values: ADA level < 10 U/L (units per liter) is generally considered normal or negative for tuberculous pericarditis
- Units of Measurement: U/L (units per liter); some laboratories may report IU/L (international units per liter)
- Cutoff Values: ≥ 10 U/L is typically considered positive/elevated and suggestive of tuberculous pericarditis; cutoff may vary slightly between laboratories and patient populations
- Result Interpretation: Negative: ADA < 10 U/L indicates low probability of tuberculous pericarditis; Positive: ADA ≥ 10 U/L suggests tuberculous etiology; Borderline results (8-12 U/L) may require clinical correlation and additional testing
- Normal vs Abnormal: Normal pericardial fluid typically has minimal ADA activity; elevated ADA activity reflects lymphocytic inflammation characteristic of tuberculosis, where T lymphocytes release ADA as part of immune response
Interpretation
- ADA < 10 U/L (Negative Result): Low probability of tuberculous pericarditis; suggests alternative diagnoses such as malignant, autoimmune, viral, or idiopathic pericarditis; does not completely exclude TB but makes it less likely
- ADA ≥ 10 U/L (Positive Result): High sensitivity and specificity for tuberculous pericarditis; strong indicator of TB etiology; requires clinical correlation with symptoms, imaging findings, and other laboratory results for diagnosis confirmation
- Very High ADA (> 20 U/L): Strongly suggestive of tuberculous pericarditis; indicates marked lymphocytic inflammation; warrants immediate antimicrobial therapy consideration
- Factors Affecting Results: Stage of disease (early vs established TB); immune status of patient (immunocompromised may have false negatives); presence of concurrent malignancy; inflammatory conditions (rheumatoid arthritis, lupus); timing of specimen collection; laboratory methodology variations
- Diagnostic Accuracy: Sensitivity 85-100% for TB pericarditis; Specificity 75-100%; superior to other markers in high TB prevalence areas; must be interpreted with clinical context and additional diagnostic tests (PCR, culture, imaging)
- Clinical Significance: High ADA supports diagnosis and may warrant empiric anti-tuberculous therapy; negative result does not exclude TB but reduces suspicion; used for risk stratification and treatment decisions in endemic areas
Associated Organs
- Primary Organ System: Cardiovascular system, specifically the pericardium (fibrous sac surrounding the heart); test analyzes fluid from pericardial space
- Associated Conditions - Tuberculous Etiology: Tuberculosis (primary causative organism); tuberculous pericarditis; cardiac tamponade from TB; constrictive pericarditis (TB-related); miliary TB with cardiac involvement; disseminated TB
- Associated Conditions - Non-Tuberculous Etiologies: Malignant pericardial effusion; viral pericarditis; autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis); uremic pericarditis; post-cardiac injury syndrome; bacterial pericarditis; fungal pericarditis
- Related Organ Involvement in TB: Lungs (primary TB site); lymph nodes (mediastinal lymphadenitis); pleura (pleural effusion); potential for systemic dissemination affecting multiple organs
- Potential Complications of Abnormal Results: Cardiac tamponade (life-threatening); constrictive pericarditis (chronic restriction of cardiac filling); severe arrhythmias; heart failure; cardiogenic shock; myocardial involvement; mortality if untreated tuberculosis progresses
- Clinical Implications: High ADA warrants urgent evaluation for hemodynamic compromise; may necessitate repeat pericardiocentesis; requires initiation of anti-tuberculous therapy; necessitates imaging follow-up (echocardiography, cardiac MRI); may require cardiology consultation
Follow-up Tests
- Immediate Confirmatory Tests: MTB PCR (Mycobacterium tuberculosis polymerase chain reaction) on pericardial fluid; AFB smear microscopy (acid-fast bacillus staining); pericardial fluid culture for TB (takes 2-8 weeks); TB culture sensitivity testing
- Complementary Pericardial Fluid Analysis: Cell count and differential; protein and glucose levels; LDH (lactate dehydrogenase); cytology for malignancy; Gram stain and bacterial culture; fungal stains and cultures; immunological markers
- Systemic TB Assessment Tests: Interferon-gamma release assay (IGRA) or tuberculin skin test (TST); blood cultures; sputum samples for AFB and TB culture; urinalysis and urine culture; bone marrow biopsy if disseminated TB suspected
- Imaging Studies: Transthoracic echocardiography (assess pericardial effusion and cardiac function); cardiac MRI (pericardial characterization); chest X-ray (evaluate for pulmonary TB); CT chest (detect mediastinal involvement and lung disease)
- Baseline Laboratory Monitoring: Complete blood count (CBC); renal function (creatinine, BUN); liver function tests (ALT, AST, bilirubin); HIV testing if not known; CD4 count in HIV-positive patients
- Treatment Monitoring (if TB diagnosed): Repeat echocardiography (assess response to therapy); serial chest imaging (document pulmonary improvement); liver function tests (monitor for drug toxicity); repeat pericardiocentesis only if clinical deterioration; imaging at 6-12 months to confirm resolution
- Recommended Monitoring Schedule: Initial intensive monitoring during first 2 weeks; monthly clinical and imaging assessment during intensive TB therapy (2 months); then every 2-3 months during continuation phase; long-term follow-up for 24 months minimum or longer for constrictive complications
Fasting Required?
- Fasting Requirement: NO - Fasting is not required for pericardial fluid ADA testing. The test involves analysis of fluid obtained directly from the pericardial space, not blood sampling.
- Sample Collection Method: Performed via pericardiocentesis (needle aspiration of pericardial fluid); typically done under ultrasound or echocardiographic guidance; sterile technique essential; patient positioned supine or semi-upright
- Pre-Procedure Patient Preparation: Informed consent required; baseline vital signs and cardiac assessment; electrocardiogram (ECG) before procedure; light meal acceptable unless general anesthesia planned; empty bladder; chest X-ray to confirm effusion; echocardiogram to localize effusion and assess hemodynamics
- Medications - Important Considerations: Hold anticoagulants (warfarin, apixaban) 48-72 hours before procedure if possible; discontinue antiplatelet agents (aspirin, clopidogrel) 5-7 days prior if clinically feasible; notify physician of all medications, especially those affecting coagulation; continue essential cardiac medications unless otherwise instructed
- Special Precautions for Sample Collection: Coagulation profile (PT/INR, PTT) may be checked beforehand; platelet count should be acceptable (>30,000/μL); local anesthesia typically used; sterile technique mandatory; appropriate sterile containers with preservatives (EDTA tube for cell count, plain tube for chemistry); maintain sterile conditions to prevent contamination
- Post-Procedure Instructions: Bed rest for 4-6 hours after procedure; vital signs monitoring; observation for complications; normal diet when stable; avoid strenuous activity for 24 hours; report chest pain, dyspnea, or hemodynamic instability immediately; follow-up echocardiogram if clinically indicated
- Special Populations: Anticoagulated patients: may require temporary reversal; thrombocytopenic patients: platelet transfusion may be needed; hemodynamically unstable patients: procedure done urgently in monitored setting; pregnant patients: risk-benefit assessment required; immunocompromised patients: heightened infection precautions

How our test process works!